On the other hand, SGLT2-i are indicated and reimbursed not only in T2DM patients but also in HF patients with reduced or preserved EF, as well as in CKD patients, regardless of the presence of T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.